ClinicalTrials.gg
RecruitingNCT06075823MILLENNIALUpdated Oct 16, 2026

Edge-to-edge Mitral Valve Repair in ATTR-CM

An interventional study of TEER and Optimal Medical Therapy in Mitral Regurgitation, ATTR-Cardiomyopathy and Edge-to-Edge Mitral Valve Repair, sponsored by Medical University of Vienna. Recruiting at 10 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Medical University of Vienna · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Oct 16, 2026Now RecruitingFirst sites in Austria, Germany and Italy+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Mitral Valve Insufficiency with a site in Austria — 6 open to participants now, 8 under way, none of them phase 3. Mitral Valve Insufficiency · Austria.

Started
2024
with 1 other
No phase
8 of 15
3 open now
Registered
13th of 15
by date
Lead sponsor
4 of 15
Medical University of Vienna

Among the 15 studies in Mitral Valve Insufficiency with a site in Austria, this one is one of 2 that started in 2024, is one of 8 with no phase, and was the 13th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

6 of the 15 studies in Mitral Valve Insufficiency with a site in Austria are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Mitral Valve Insufficiency with a site in Austria, or all of them as a file.
02

Study summary

No previous study has evaluated the effectiveness of transcatheter edge-to-edge mitral valve repair (TEER) in patients with ATTR-associated cardiomyopathy (ATTR-CM) and significant mitral regurgitation, as this specific patient population was specifically excluded from previous large TEER trials. From a pathophysiological perspective, effective treatment of significant regurgitant volume and consecutive improvement of forward volume appears highly desirable in a condition with intrinsically low output. However, whether this translates into improved functional capacity, better quality of life, and better clinical outcomes compared to conservative heart failure management alone remains to be investigated.

Read the detailed description

MILLENNIAL is an investigator-initiated, multicentre, prospective, parallel-group, open-label, randomized controlled trial. Patients with proven ATTR-CM and concomitant significant (moderate-to-severe or severe) symptomatic mitral regurgitation, in whom the local heart team has ruled out mitral valve surgery and who are anatomically suitable for TEER, are randomized 1:1 to TEER plus optimal medical therapy (OMT) or OMT alone. Randomization is performed centrally with permuted blocks of variable size (4-8), stratified by the presence of significant tricuspid regurgitation and NYHA class ≥III. ATTR-specific therapy is allowed in both arms at the discretion of the treating physician. Cross-over is not permitted within the first year.

The primary endpoint is a hierarchical composite assessed at 12 months, analysed with the Finkelstein-Schoenfeld method (win ratio as effect measure, stratified by National Amyloidosis Centre stage): (1) all-cause mortality, (2) cumulative frequency of unplanned cardiovascular hospitalizations, (3) change from baseline in 6-minute walk distance (win threshold ≥30 m), (4) change from baseline in KCCQ Overall Summary score (win threshold ≥5 points). Heart transplantation, combined heart-liver transplantation and durable mechanical circulatory support are counted as death. Change in NT-proBNP is the key secondary endpoint; technical, device and procedural success (MVARC) are safety endpoints. Exploratory endpoints include intraprocedural invasive haemodynamics before and after device deployment and advanced echocardiographic indices of myocardial performance.

A sample size of 106 patients (53 per arm) provides 80% power at a two-sided alpha of 0.05 for an assumed win ratio of 2.1, including 10% cross-over and 5% drop-out. Study visits take place at baseline, 6 months (±7 days) and 12 months (±14 days). Interim analyses are performed after every 25 patients and reviewed by an independent data monitoring committee; a pre-specified futility analysis is performed once 50 patients have completed 12-month follow-up (stop if conditional power \<10%).

03

Conditions studied

  • Mitral Regurgitation
  • ATTR-Cardiomyopathy
  • Edge-to-Edge Mitral Valve Repair
04

Who can participate

The criteria were revised on the registry on Oct 16, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Proven ATTR-CM
  • Significant symptomatic MR (3+ or 4+ by independent echocardiographic core laboratory assessment)
  • Subject has been adequately treated per applicable standards, including for coronary artery disease and heart failure (e.g., diuretics)
  • (NYHA) functional class II, III, or ambulatory IV
  • Local heart team has determined that mitral valve surgery will not be offered as a treatment option, even if the subject is randomized to the control group
  • ≥20%
  • Anatomical feasibility for TEER as per discretion of the implanting investigator
  • Age 18 years or older
  • Subject or guardian agrees to all provisions of the protocol, including the possibility of randomization to the Control group and returning for all required post-procedure follow-up visits, and has provided written

Exclusion criteria

Exclusion criteria (all must be absent)

  • AL-associated cardiomyopathy
  • Aortic valve disease requiring surgery or transcatheter intervention
  • Severe right ventricular dysfunction
  • Hemodynamic instability requiring inotropic support or mechanical heart assistance
  • Leaflet anatomy which may preclude TEER, proper device positioning on the leaflets or sufficient reduction in mitral regurgitation by TEER
  • \<12 months due to non-cardiac conditions
  • Prior mitral valve leaflet surgery or any currently implanted prosthetic mitral valve, or any prior transcatheter mitral valve procedure
  • Echocardiographic evidence of intracardiac mass, thrombus or vegetation
  • Active endocarditis or active rheumatic heart disease or leaflets degenerated from rheumatic disease (i.e., noncompliant, perforated)
  • Active infections requiring current antibiotic therapy
  • Transesophageal echocardiography (TEE) is or high risk
  • Pregnant or planning pregnancy within next 12 months
  • Currently participating in another device study that has not reached its primary endpoint
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
106 participants (estimated)

Study arms

  • Experimental
    Interventional

    TEER + Optimal Medical Therapy

    Device: TEER · Other: Optimal Medical Therapy

  • Active comparator
    Control

    Optimal Medical Therapy alone

    Other: Optimal Medical Therapy

Interventions

  • DeviceTEER

    Transcatheter edge-to-edge mitral valve repair under general anaesthesia with transoesophageal echocardiographic and fluoroscopic guidance; up to three newer-generation MitraClip (NTR, XTR; Abbott) or PASCAL (Edwards Lifesciences) devices to maximally reduce mitral regurgitation. Intraprocedural invasive haemodynamic measurements before and after device deployment.

  • OtherOptimal Medical Therapy

    Optimal medical therapy according to the current understanding of heart failure management in ATTR-CM (careful volume management, rate/rhythm control in atrial fibrillation, anticoagulation where indicated). ATTR-specific therapy (e.g. tafamidis, acoramidis) is allowed but not mandatory in both arms at the discretion of the treating physician; all heart failure and ATTR-specific medication is recorded at every visit.

06

What researchers measure

Primary outcomes

  1. Hierarchical composite of all-cause mortality, cumulative frequency of unplanned cardiovascular-related hospitalizations, change from baseline in 6-minute walk distance, and change from baseline in KCCQ Overall Summary score through month 12

    Each subject in the TEER+OMT group is compared with each subject in the OMT group in a pairwise manner, within strata defined by National Amyloidosis Centre disease stage (I, II, III) at baseline, in hierarchical order: (1) all-cause mortality (heart transplantation, combined heart-liver transplantation and implantation of a durable mechanical cardiac-assist device count as death); (2) cumulative frequency of unplanned cardiovascular-related hospitalizations, compared over the shorter follow-up time of the pair; (3) change from baseline in 6-minute walk distance, a difference of ≥30 m defining a win (smaller differences are ties); (4) change from baseline in the Kansas City Cardiomyopathy Questionnaire Overall Summary score (0-100, higher = better health status), a difference of ≥5 points defining a win. Statistical significance is tested with the Finkelstein-Schoenfeld method at a two-sided alpha of 0.05; the win ratio quantifies the treatment effect.

    Time frame: 12 months

Secondary outcomes

  1. Change from baseline in NT-proBNP (key secondary endpoint)

    Change from baseline in N-terminal pro-B-type natriuretic peptide (pg/mL), analysed with a mixed-effects model for repeated measures / analysis of covariance with treatment group and visit as fixed effects and the baseline value as covariate.

    Time frame: Baseline, 6 months and 12 months

  2. Technical, device, and procedural success of TEER (in the TEER group only)

    Technical, device, and procedural success of TEER as defined according to the definitions of the Mitral Valve Academic Research Consortium (MVARC)

    Time frame: Technical success at exit from the procedure room; device and procedural success at 6 and 12 months

Other outcomes

  1. Change from baseline in echocardiographic indices of myocardial performance and remodelling

    Change from baseline in left ventricular ejection fraction, forward stroke volume, global longitudinal strain, tissue Doppler-derived systolic and diastolic velocities and diastolic function indices, left atrial strain, myocardial contraction fraction (left ventricular stroke volume/myocardial volume) and left ventricular stroke work index, assessed by a blinded echocardiographic core laboratory.

    Time frame: Baseline, 6 months and 12 months

  2. Acute intraprocedural change in invasive haemodynamics (TEER group only)

    Change in forward stroke volume, cardiac output and cardiac index, right atrial pressure, pulmonary artery pressures, pulmonary capillary wedge pressure, and pulmonary and systemic vascular resistance measured with standard catheterization laboratory equipment immediately before and after device deployment. Sub-analyses will assess cut-offs of acute haemodynamic change that identify responders with regard to myocardial performance and clinical outcome.

    Time frame: Intraprocedural (immediately before and after device deployment)

07

Study locations

8 of 10 sites recruiting
08

References and documents

Publications

  • Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B, Grayburn PA, Rinaldi M, Kapadia SR, Rajagopal V, Sarembock IJ, Brieke A, Marx SO, Cohen DJ, Weissman NJ, Mack MJ; COAPT Investigators. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med. 2018 Dec 13;379(24):2307-2318. doi: 10.1056/NEJMoa1806640. Epub 2018 Sep 23. PubMed 30280640 ↗
  • Dona C, Nitsche C, Koschutnik M, Heitzinger G, Mascherbauer K, Kammerlander AA, Dannenberg V, Halavina K, Rettl R, Duca F, Traub-Weidinger T, Puchinger J, Gunacker PC, Lamm G, Vock P, Lileg B, Philipp V, Staudenherz A, Calabretta R, Hacker M, Agis H, Bartko P, Hengstenberg C, Fontana M, Goliasch G, Mascherbauer J. Unveiling Cardiac Amyloidosis, its Characteristics, and Outcomes Among Patients With MR Undergoing Transcatheter Edge-to-Edge MV Repair. JACC Cardiovasc Interv. 2022 Sep 12;15(17):1748-1758. doi: 10.1016/j.jcin.2022.06.009. Epub 2022 Aug 22. PubMed 36008266 ↗
  • Chacko L, Karia N, Venneri L, Bandera F, Passo BD, Buonamici L, Lazari J, Ioannou A, Porcari A, Patel R, Razvi Y, Brown J, Knight D, Martinez-Naharro A, Whelan C, Quarta CC, Manisty C, Moon J, Rowczenio D, Gilbertson JA, Lachmann H, Wechelakar A, Petrie A, Moody WE, Steeds RP, Potena L, Riefolo M, Leone O, Rapezzi C, Hawkins PN, Gillmore JD, Fontana M. Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. Eur J Heart Fail. 2022 Sep;24(9):1700-1712. doi: 10.1002/ejhf.2606. Epub 2022 Jul 27. PubMed 35779241 ↗
  • Nitsche C. Echocardiographic tracking of transthyretin cardiomyopathy: which parameters matter the most? Eur J Heart Fail. 2022 Sep;24(9):1713-1715. doi: 10.1002/ejhf.2639. Epub 2022 Aug 12. No abstract available. PubMed 35906799 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2027, 47 months after the start.

Of 144 interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 108. This study's planned 47 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2023
First posted
Oct 10, 2023
StartActual
Jan 1, 2024
Primary completionEst.
Dec 12, 2027
CompletionEst.
Dec 12, 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
10 sites added — first sites in Austria, Germany and Italy
Show 10 added (5 Austria, 3 Germany, 2 Italy)
  • Medical University of Graz, Division of Cardiology · Graz, Austria
  • Ordensklinikum Linz Elisabethinen, Internal Medicine 2, Cardiology · Linz, Austria
  • University Hospital St. Pölten, Department of Internal Medicine 3 · Sankt Pölten, Austria
  • Clinic Favoriten, 5th Medical Department, Cardiology · Vienna, Austria
  • Medical University of Vienna · Vienna, Austria
  • Hannover Medical School, Department of Cardiology and Angiology · Hanover, Germany
  • University Hospital Heidelberg, Department of Cardiology, Angiology and Respiratory Medicine · Heidelberg, Germany
  • LMU University Hospital, Department of Medicine I · München, Germany
  • ASST Papa Giovanni XXIII, Cardiovascular Department · Bergamo, Italy
  • ASST Spedali Civili di Brescia, Cardiology · Brescia, Italy
Oct 16, 2026
Enrollment
100→106
Oct 16, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedAortic or tricuspid valve disease requiring surgery or transcatheter intervention
Oct 16, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedA hierarchical combinationHierarchical composite of all-cause mortality, cumulative frequency of unplanned cardiovascular-related hospitalizationhospitalizations, change from baseline in NT6-proBNPminute walk distance, and change from baseline in 6MWTKCCQ Overall Summary score through month 2412Time frame: 24 months → 12 months
Oct 16, 2026
Secondary outcomes
3 edited, 1 time frame changed
What changed in the outcomes
  • ChangedBefore Evaluate effects of TEER on quality of life (QoL) through Month 24Now Change from baseline in NT-proBNP (key secondary endpoint)Time frame: 24 months → Baseline, 6 months and 12 months
  • Time frameTechnical, device, and procedural success of TEER (in the TEER group only)12 months → Technical success at exit from the procedure room; device and procedural success at 6 and 12 months
  • Editedother outcomeEffects of TEER onAcute intraprocedural change in invasive haemodynamics (in the TEER group only)Time frame: 1 day → Intraprocedural (immediately before and after device deployment)
  • Changedother outcomeBefore Effects of TEER on echocardiographic markersNow Change from baseline in echocardiographic indices of myocardial performance and remodellingTime frame: 24 months → Baseline, 6 months and 12 months
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Not yet recruiting→Recruiting
    10 sites added — first sites in Austria, Germany and Italy
    Show 10 added (5 Austria, 3 Germany, 2 Italy)
    • Medical University of Graz, Division of Cardiology · Graz, Austria
    • Ordensklinikum Linz Elisabethinen, Internal Medicine 2, Cardiology · Linz, Austria
    • University Hospital St. Pölten, Department of Internal Medicine 3 · Sankt Pölten, Austria
    • Clinic Favoriten, 5th Medical Department, Cardiology · Vienna, Austria
    • Medical University of Vienna · Vienna, Austria
    • Hannover Medical School, Department of Cardiology and Angiology · Hanover, Germany
    • University Hospital Heidelberg, Department of Cardiology, Angiology and Respiratory Medicine · Heidelberg, Germany
    • LMU University Hospital, Department of Medicine I · München, Germany
    • ASST Papa Giovanni XXIII, Cardiovascular Department · Bergamo, Italy
    • ASST Spedali Civili di Brescia, Cardiology · Brescia, Italy
    Enrollment 100→106
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedAortic or tricuspid valve disease requiring surgery or transcatheter intervention
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedA hierarchical combinationHierarchical composite of all-cause mortality, cumulative frequency of unplanned cardiovascular-related hospitalizationhospitalizations, change from baseline in NT6-proBNPminute walk distance, and change from baseline in 6MWTKCCQ Overall Summary score through month 2412Time frame: 24 months → 12 months
    Secondary outcomes 3 edited, 1 time frame changed
    What changed in the outcomes
    • ChangedBefore Evaluate effects of TEER on quality of life (QoL) through Month 24Now Change from baseline in NT-proBNP (key secondary endpoint)Time frame: 24 months → Baseline, 6 months and 12 months
    • Time frameTechnical, device, and procedural success of TEER (in the TEER group only)12 months → Technical success at exit from the procedure room; device and procedural success at 6 and 12 months
    • Editedother outcomeEffects of TEER onAcute intraprocedural change in invasive haemodynamics (in the TEER group only)Time frame: 1 day → Intraprocedural (immediately before and after device deployment)
    • Changedother outcomeBefore Effects of TEER on echocardiographic markersNow Change from baseline in echocardiographic indices of myocardial performance and remodellingTime frame: 24 months → Baseline, 6 months and 12 months
    + 7 other changes: identifiers, verification date, date precision, responsible party, description, arm descriptions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06075823
Collaborators
Austrian Science Fund (FWF)
Responsible party
Christian Nitsche (Principal Investigator, Medical University of Vienna) — Principal investigator
First posted
Oct 10, 2023
Start date
Jan 1, 2024
Primary completion
Dec 12, 2027 (estimated)
Completion
Dec 12, 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

Christian Nitsche, MD, PhD
Contact
christian.nitsche@meduniwien.ac.at
0043 1 40400 46142
Christian Nitsche, MD, PhD
principal investigator · Medical University of Vienna

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion